Evolus (EOLS) Cash from Operations Growth (3y) (2020 - 2026)
Evolus (EOLS) Cash from Operations Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.83 Bn | 32.09 Bn | 1.97 Bn | 34.90% |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn | -9.94% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | -10.80% |
| 5 | United Therapeutics | 23.14 Bn | 20.99 Bn | 648.10 Mn | 7.32% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | -26.33% |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn | 46.81% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | 27.85% |
| 10 | Evolus | 401.22 Mn | 351.43 Mn | 48.90 Mn | 21.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.52% |
| Dec 31, 2025 | 51.28% |
| Sep 30, 2025 | 4.89% |
| Jun 30, 2025 | -5.88% |
| Mar 31, 2025 | 25.76% |
| Dec 31, 2024 | 36.29% |
| Sep 30, 2024 | 43.74% |
| Jun 30, 2024 | -33.91% |
| Mar 31, 2024 | -8.39% |
| Dec 31, 2023 | 33.12% |
| Sep 30, 2023 | 59.31% |
| Jun 30, 2023 | 1.54% |
| Mar 31, 2023 | 9.69% |
| Dec 31, 2022 | 18.02% |
| Sep 30, 2022 | 12.10% |
| Jun 30, 2022 | 14.28% |
| Mar 31, 2022 | -25.77% |
| Dec 31, 2021 | 9.01% |
| Sep 30, 2021 | -77.33% |
| Jun 30, 2021 | 69.01% |